About: http://data.cimple.eu/news-article/a4f8a5a4662aeabee8dec41bf6647cdd820f4feb146f54bc28d43464     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • The maker of anti-influenza drug Avigan said Wednesday it will apply for the medication to be approved for treating coronavirus patients after trials showed it can shorten recovery time. In a statement, manufacturer Fujifilm Toyama Chemical said its phase III trial in Japan, which began in March, was now complete. Of 156 individuals described as "analysis targets", the median recovery time was 11.9 days in those receiving Avigan compared with 14.7 for patients given a placebo. Recovery was defined in the trial as when the virus was no longer detectable in PCR tests, and when symptoms related to temperature, oxygen saturation and chest imaging were improved. The "randomised, placebo-controlled, single-blind comparative study" did not produce any new safety concerns, Fujifilm said. The firm said it would now "conduct a detailed analysis of the data obtained in this trial, and will work to file Application for Partial Changes to include the additional indication in as early as October." The drug, whose generic name is favipiravir, was approved for use in Japan in 2014, but only in flu outbreaks that are not effectively addressed by existing medications. It is not available on the market and can only be manufactured and distributed at the request of the Japanese government. Favipiravir, which can be taken orally as a pill, works by blocking the ability of a virus to replicate inside a cell. Avigan has been shown in animal studies to affect foetal development, meaning it is not given to pregnant women. Japan has heavily backed the drug, asking Fujifilm to ramp up production for use at home and offering to supply it for free to dozens of countries that have put in requests. sah/kaf/rbu
schema:headline
  • Avigan maker to seek virus treatment approval after trials
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...romotesConspiracy
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software